Germany - Drugs

Description

Conclusion of non-exclusive discount agreements in accordance with Section 130a (8) SGB V with the possibility of conclusion at any time within the framework of so-called "open house procedures" for various active pharmaceutical ingredients with the earliest possible start of the contract on 01.10.2022..The specific active pharmaceutical ingredients and the respective contract start dates can be found in the current list of active pharmaceutical ingredients in the project room of the dtvp award portal under the heading "Award documents"..Contracts will be offered for the following active pharmaceutical ingredients on 01.10.2022:.Abacavir / Lamivudine / ZidovudineAcetylcysteine_non-RX non-RXAcetylcysteine_RX RXAcetylsalicylic acid exclusively according to Annex 1 AM-RL G-BA prescribable productsAcitretinAdefovir dipivoxilAlitretinoinAmifampridineAnagrelide except N3 packs of DAR HKP with 0,5 mg active strengthAripiprazole except DAR tablets/meltablets and oral solutionsAtorvastatin/ezetimibeBeclometasone/formoterolBeclometasone/formoterol/glycopyrroniumBimatoprostBiperidenBortezomibBrivudineBudesonide except inhalativesCalcipotriolCalcium/colecalciferolCeftriaxoneClomipramine 75 mg active strength, retardedClostridium botulinum except lifestyle drugsColecalciferol non-RXColecalciferol RXColistinCyproteroneDeferasiroxDesloratadineDesogestrel / EthinylestradiolDienogestDienogest / EthinylestradiolDiltiazemDistigmineDornase alphaDronedaroneDrospirenone / EthinylestradiolEbastineEisen II oral DAR/exclusively according to Annex 1 AM-RL G-BA prescribable productsEnoxaparin 20 mg and 40 mg 20 mg and 40 mg effective strengthEnoxaparin 60 mg, 80 mg and 100 mg 60 mg, 80 mg and 100 mg active strengthErtugliflozinErythropoietin EpoetinEslicarbazepineEstradiolEtanerceptEtravirinEverolimusFampridineFentanylFilgrastimFlupentixol decanoateFollitropin alfaFollitropin betaFondaparinux sodiumFusidic acidFusidic acid / betamethasoneGlatiramer acetate (40mg active strength DAR PEN)GoserelinHydrocortisoneHydromorphone DAR Injection-/infusion solutionHydroxychloroquineHydroxyzineIbuprofen (non-RX, liquid oral dosage forms)Ibuprofen (RX 400mg and 600mg)Ibuprofen (RX 800 mg sustained release)Ibuprofen (RX 800mg non sustained release)ImatinibInfliximabInterferon beta 1a Avonex(R)Interferon beta 1a Rebif(R)LanreotideLenalidomideLenograstimLeuprorelinLidocaine DAR patchLipegfilgrastimLoperamideLopinavir / RitonavirMacrogol only according to Appendix 1 AM-RL G-BA prescribable productsMacrogol exclusively according to Annex 5 AM-RL G-BA prescribable medical devicesMeloxicamMeropenemMethocarbamol except DAR film-coated tablets with 750 mg active ingredient strengthMetoclopramideMidazolamMinocyclineNadroparinNatalizumab except subcutaneous useNitisinonOctreotideOlmesartan / Amlodipine / HCTOxycodone / NaloxonePaliperidonePalonosetronPancreatinParacetamol exclusively according to Annex 1 AM-RL G-BA prescribable productsPegfilgrastimPeginterferon beta-1aPemetrexedPerindopril / IndapamidPerindopril/ AmlodipinePromethazinePyridostigmineRabeprazoleRaltegravirRisperidone only dry substances with solvent and powder and solvent for preparation of a solution for injection solution for injectionRitonavirRituximabRoflumilastRosuvastatin/EzetimibRotigotineRupatadineSilodosineSomatropinSorafenibSulfasalazineSunitinibTacrolimusTadalafil indication BP onlyHTapentadolTeriparatideTimolol / Bimatoprost DAR eye drops in single dose containerTiotropium bromide Inh.lsgTobramycinTolvaptanTramadol / ParacetamolTrastuzumabTravoprost / TimololTriptorelinZidovudineZolmitriptan.The contracts end uniformly on Sept. 30, 2024.
The AOK Rheinland/Hamburg announces the conclusion of non-exclusive discount agreements in accordance with Section 130a (8) of the German Social Code, Book V (SGB V) with the possibility of conclusion at any time within the framework of so-called "open house procedures" for various active pharmaceutical ingredients with the earliest possible start of the contract on October 1, 2022.The specific active pharmaceutical ingredients and the respective earliest possible contract start dates can be found in the current list of active pharmaceutical ingredients in the project room of the dtvp procurement portal under the heading "Procurement documents"...Under the specification of uniform contract conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement pursuant to Section 130a Para. Interested pharmaceutical companies can obtain the participation documents in the project room of the DTVP procurement portal under the heading "Procurement documents".A prerequisite for the conclusion of a contract is that the interested pharmaceutical company completes and signs the requested participation documents and sends them to the following e-mail box sendet:.open-house@rh.aok.de..Über. This e-mail box will be used for any exchange of documents for the implementation of the OpenHouse procedure between the companies and the Pharmaceuticals Division of the AOK Rheinland/Hamburg..A contract will be concluded with each pharmaceutical company that meets the participation requirements. Exclusivity is not given. Joining or concluding a contract can be done at any time and under the same conditions. Individual contract negotiations are not conducted..The earliest contract start date is 01.10.2022. The conclusion or joining of a discount contract is possible at any time, i.e. also after 01.10.2022. The contract period ends uniformly on 30.09.2024, irrespective of the individual contract start date..The list of active ingredients covered by the contract is changed at irregular intervals. In this case, all companies verified in the project space in the DTVP procurement portal will receive an e-mail with a note indicating which active ingredients have been added and when the respective, earliest possible contract start date is.Should the AOK Rheinland/Hamburg conduct a tender for exclusive contracts in the form of an EU-wide, open procedure during the contract term, the contracts concluded as part of this publication will be terminated in accordance with the contractual provisions..This publication does not constitute the award of a public contract within the meaning of the Public Procurement Coordination Directive (2014/24/EC) or public procurement law. In order to ensure the highest degree of transparency for the intended contract conclusions, the publication is made in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice is used. The resulting conceptual specifications, such as the procedure designation "open procedure", are solely due to the use of this publication form and the publication platform. A further meaning, in particular a subjection to procurement law regulations, as far as they are not obligated for legal reasons, is not connected with it.

Opportunity closing date

31 August 2024

Value of contract

to be confirmed